KMDA

KMDA

USD

Kamada Ltd. Ordinary Shares

$6.660+0.040 (0.604%)

リアルタイム価格

Healthcare
Drug Manufacturers - Specialty & Generic
イスラエル

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$6.620

高値

$6.738

安値

$6.590

出来高

0.01M

企業ファンダメンタルズ

時価総額

383.0M

業種

Drug Manufacturers - Specialty & Generic

Israel

取引統計

平均出来高

0.20M

取引所

NMS

通貨

USD

52週レンジ

安値 $4.74現在値 $6.660高値 $9.15

AI分析レポート

最終更新: 2025年5月2日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

KMDA (Kamada Ltd. Ordinary Shares): Analyzing Recent Moves & What Might Come Next

Stock Symbol: KMDA Generate Date: 2025-05-02 16:53:37

Alright, let's break down what's been happening with Kamada stock lately, looking at the news, how the price has moved, and what some of the automated tools are suggesting. Think of this as getting the lowdown on the situation.

Recent News Buzz - What's the Vibe?

The news coming out about Kamada recently has been overwhelmingly positive. Seriously, it's been a string of good stuff.

First off, the company reported its financial results for 2024, and they were strong – record revenue and profit growth, plus they stuck to their forecast for more double-digit growth in 2025. That's a big deal; it tells you the business is doing well and expects to keep growing.

Then, they announced they're opening a new plasma collection center in Texas. This is important because plasma is key to their products. Expanding collection means they're boosting their ability to make and sell more stuff down the road. It's a move aimed at future growth.

Adding to the good news, a firm called Benchmark just started covering Kamada stock and slapped a "Buy" rating on it with a price target way up at $15. When an analyst initiates coverage with a positive rating and a high target, it often grabs attention and can signal confidence from Wall Street.

Finally, there was news about the procedures for a special cash dividend. While maybe not as exciting as growth news, the fact they paid a dividend at all is another positive sign, suggesting the company is in a solid enough financial position to return cash to shareholders.

So, the overall feeling from the news flow is definitely upbeat.

Price Action - What's the Stock Been Doing?

Looking at the stock chart over the last month or two, it's been a bit of a rollercoaster, but it seems to have settled down recently.

Back in early February, the price shot up quite dramatically, hitting highs near $8.90. That was a big jump! But after that spike, it pulled back pretty significantly, trading mostly between $6.50 and $7.20 through March.

More recently, in April and early May, the stock has been trading in a tighter range, mostly hanging out between $6.50 and $6.80. It's been relatively stable in this area.

The current price is sitting right around $6.70. Comparing this to the recent trend, it's right in the middle of that recent sideways movement.

Now, what about the AI's take? The prediction for today is basically flat (0.00%), which lines up with the recent stability. But the AI forecasts a move up over the next couple of days – predicting a 2.07% increase tomorrow and a 3.13% increase the day after. That suggests the AI sees potential for the stock to nudge higher from its current level.

Putting It Together - Potential Outlook & Strategy Ideas

So, here's the picture we get when we combine the news, the price history, and the AI's forecast:

The company itself seems to be firing on all cylinders based on the financial results and expansion plans. Wall Street is taking notice with a positive rating and a high long-term target. The stock price had its big move and pullback, and now it's been consolidating in a range. The AI is predicting a slight upward push from here.

Based on all this, the apparent near-term leaning seems to be cautiously positive. The strong fundamentals and positive news could provide a tailwind, and the AI prediction supports the idea of some upward movement from the current level.

Potential Entry Consideration: If you were considering this stock, the current price area, around $6.70, looks interesting because the AI prediction starts its upward forecast from here. Also, the recommendation data pointed to entry points slightly lower ($6.56, $6.61), which are within the recent trading range. A strategy might be to consider the current level or look for a slight dip back towards the $6.50-$6.60 area, which has acted as a floor recently.

Potential Exit/Stop-Loss Consideration: For managing risk, the recommendation data suggests a stop-loss level at $5.92. This is below the recent trading range and offers protection if the stock breaks down significantly. On the upside, the AI predicts a few percent gain over the next couple of days. The recommendation data gives a take profit of $6.71, which seems very conservative given the current price and AI forecast. A more ambitious potential take profit could be based on the AI's projected percentage increase applied to the current price, or perhaps looking towards the upper end of the recent trading range or even the levels seen in early March (around $7.00-$7.20) if the positive momentum builds. Remember the analyst target is $15, but that's likely a much longer-term view.

Company Context

Just to keep in mind, Kamada is a biopharmaceutical company that makes medicines from plasma. Things like expanding plasma collection are directly tied to their core business and future capacity. The positive financial results show they're executing on their strategy in this specific area.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves risk, and you could lose money. Always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

関連ニュース

GlobeNewswire

Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious

もっと見る
Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders
Analyst Upgrades

Benchmark Initiates Coverage On Kamada with Buy Rating, Announces Price Target of $15

Benchmark analyst Robert Wasserman initiates coverage on Kamada with a Buy rating and announces Price Target of $15.

もっと見る
Benchmark Initiates Coverage On Kamada with Buy Rating, Announces Price Target of $15
GlobeNewswire

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-DSpecialty

もっと見る
Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas
GlobeNewswire

Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA of $34.1 Million, Up 42% Year-over-Year, and a 21% Margin of RevenuesCash Provided by

もっと見る
Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

AI予測Beta

AI推奨

強気

更新日時: 2025年5月3日 15:19

弱気中立強気

64.6% 信頼度

リスクと取引

リスクレベル3/5
中リスク
適しているのは
中程度
取引ガイド

エントリーポイント

$6.66

利確

$7.19

損切り

$6.02

主要因子

PDI 17.6はMDI 14.6の上にあり、ADX 9.2とともに強気トレンドを示唆しています
現在の価格はサポートレベル(6.66ドル)に非常に接近しており、強力な買い機会を示唆しています
出来高は平均(2,134)の3.1倍で、極めて強い買い圧力を示しています
MACD 0.0012はシグナルライン0.0022の下にあり、弱気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。